TechCapsules

Menstruation in space will be studied for 1st time with ‘Operation Period’

Virgin Galactic is partnering with non-profit organization Operation Period to launch the first study dedicated to researching menstruation in microgravity. Led by Gen-Z researchers, Operation Period aims to provide "menstrual freedom" and tackle issues that leave people without access to menstrual products. The study, Operation Period-01, will be conducted on a suborbital flight in 2027 by the organization's founders, who will become some of the youngest South Asian women to travel to space. The research aims to address the current issues of menstruation in space, including the limited data on the topic and the reliance on hormonal suppression methods.

💡 This mission highlights the need for inclusive space exploration that prioritizes the health and well-being of all astronauts, regardless of their menstrual status. By collecting comprehensive data on menstruation in space, Operation Period aims to break down barriers and ensure that astronauts have access to the same opportunities and choices as their peers on Earth.

Remember Midjourney? It’s Building a Medical Scanning Device That It Says Is…

Midjourney, a company previously known for AI imagery, is rebranding itself as a wellness brand. The company is developing a body scanner technology that claims to be faster, cheaper, and less invasive than an MRI. The scanner uses ultrasonic sound waves and underwater sensors to create a detailed 3D map of the body. Midjourney plans to open a spa in downtown San Francisco, featuring a scanner as the centerpiece, and aims to provide a more comfortable and efficient health scanning experience.

💡 This marks a significant shift in Midjourney's focus from AI to wellness, and the company's ambitious claims about its scanner technology could disrupt the medical imaging industry if proven successful.

Ultrahuman seeks to define: M2 Live keeps your metabolic health close with…

Ultrahuman has announced M2 Live, a continuous glucose monitor from Abbott's Lingo, to redefine metabolic health for users. The integration brings an over-the-counter monitor to more people in the US, starting at $99 per month without a prescription. M2 Live will stream insights to the Ultrahuman app, including sleep, stress, and activity, to help users understand glucose regulation. The platform combines health markers and blood biomarkers to provide personalized insights. The feature will launch in the coming weeks in the US, with a singular Lingo biosensor available for $129. Users can wear the sensor for up to 14 days, with a monthly subscription for ongoing use.

💡 By making continuous glucose monitoring more affordable and accessible, Ultrahuman's M2 Live has the potential to revolutionize glucose management for individuals who need it most. Personalized insights into glucose regulation can help users make informed decisions about their diet and lifestyle.

Paradromics and University of Michigan Complete First Connexus® BCI Implantation for the…

Paradromics Inc., a neurotechnology company, has completed the first surgical implantation of its Connexus BCI platform in the FDA-approved Connect-One Early Feasibility Study at the University of Michigan Health. The procedure, performed by neurosurgeon Matthew Willsey, M.D., Ph.D., marks a significant milestone in the development of the brain-computer interface technology, which aims to restore speech and enable computer control for individuals with severe motor impairment. The study will evaluate the long-term use of the Connexus BCI to ensure its safety and efficacy.

💡 This breakthrough has the potential to revolutionize the lives of millions of people living with severe motor impairment, offering a new avenue for communication and independence. By successfully implanting the Connexus BCI, Paradromics is one step closer to making this technology a reality, and its implications could extend far beyond the medical field, transforming the way we interact with the world.

SEMI Smart MedTech Initiative Identifies Obstacles and Opportunities to Scale Wearable Biosensors…

The SEMI Smart MedTech Initiative has identified key obstacles hindering the widespread adoption of wearable biosensors in clinical settings. Despite rapid advancements in semiconductor technologies and edge AI, wearables struggle to scale beyond everyday wellness into clinically accepted healthcare solutions. The initiative's strategic outlook paper, Medicalizing Consumer Silicon, highlights systemic barriers such as poor integration, validation requirements, and regulatory context as primary challenges. The paper recommends collaboration across industry sectors, academia, and government to address these challenges and enable reliable and scalable adoption.

Insight Health Joins AdvancedMD Marketplace to Bring Clinical AI Agents to Thousands…

Insight Health has joined the AdvancedMD Marketplace, making its AI-powered clinical agents available to thousands of independent practices and multi-specialty groups. This partnership aims to reduce the administrative burden in healthcare by automating front-office and documentation workflows. The integration will provide AdvancedMD users with access to Insight Health's suite of clinical agents, streamlining tasks and improving efficiency. The move is significant as it brings advanced technology to a large number of healthcare providers, potentially improving patient care and reducing costs. The partnership is expected to have a positive impact on the healthcare industry, with thousands of practices set to benefit from the new technology, and is a key development in the use of AI in healthcare, with the goal of reducing administrative tasks and enhancing clinical decision-making.

💡 By automating routine tasks, healthcare providers can focus on high-value tasks that improve patient outcomes. This integration also sets a precedent for wider adoption of AI-powered solutions in healthcare, driving innovation and efficiency in the sector.